Xeris Biopharma Holdings, Inc. (XERS) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 10 analysts19.2% Below Target
XERS trades 19.2% below Wall Street's consensus target of $8.82.
Current Price$7.40
Average Target$8.82
Target
Current
Low$4.00
Median$6.60
High$18.00
Analyst Target Range
Forward P/E51.0x
(High Premium)
PEG Ratio—
Implied Growth+114.6%
(High Growth)
Analyst Spread158.7%
(Wide Disagreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes XERS achieves its forward estimates and maintains a stable P/E multiple of 51.0x. This scenario reflects the blended consensus of 10 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
XERS Price Target Analysis
Updated June 25, 2026As of June 25, 2026, Xeris Biopharma Holdings, Inc. (XERS) has a Wall Street consensus price target of $8.82, based on estimates from 10 covering analysts. With the stock currently trading at $7.40, this represents a potential upside of +19.2%. The company has a market capitalization of $1.28B.
Analyst price targets range from a low of $4.00 to a high of $18.00, representing a 159% spread in expectations. The median target of $6.60 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, XERS trades at a trailing P/E of 2312.5x and forward P/E of 51.0x. Analysts expect EPS to grow +114.6% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+36.6%
Industry Consensus
Avg Forward P/E
33.9x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 LNTHLantheus Holdings, Inc. | $6.8B | $104.85 | $108.50 | +3.5% | Buy | 19.6x | 17 |
 SUPNSupernus Pharmaceuticals, Inc. | $2.6B | $45.14 | $60.00 | +32.9% | Buy | 18.2x | 14 |
 PAHCPhibro Animal Health Corporation | $1.3B | $31.36 | $49.00 | +56.3% | Buy | 10.2x | 14 |
 CORTCorcept Therapeutics Incorporated | $8.8B | $81.56 | $83.00 | +1.8% | Buy | 139.3x | 26 |
 AMRXAmneal Pharmaceuticals, Inc. | $5.5B | $17.32 | $17.33 | +0.3% | Buy | 17.6x | 16 |
 NVONovo Nordisk A/S | $210.7B | $47.41 | $45.00 | -5.1% | Buy | 2.2x | 39 |
 LLYEli Lilly and Company | $1.1T | $1117.26 | $1271.24 | +13.8% | Buy | 30.5x | 45 |
 IONSIonis Pharmaceuticals, Inc. | $12.6B | $76.52 | $109.44 | +43.0% | Buy | — | 32 |
 PRAXPraxis Precision Medicines, Inc. | $8.9B | $308.94 | $584.00 | +89.0% | Buy | — | 16 |
 NKTRNektar Therapeutics | $1.3B | $64.89 | $149.60 | +130.5% | Buy | — | 33 |
XERS — Frequently Asked Questions
Quick answers to the most common questions about buying XERS stock.
What is the XERS stock price target for 2026?
Xeris Biopharma Holdings, Inc. (XERS) has a consensus 12-month price target of $8.82, implying 19.2% upside from $7.4. The 10 analysts covering XERS see moderate appreciation potential.
Is XERS a buy, sell, or hold?
XERS has a consensus rating of "Buy" based on 10 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $8.82 implies 19.2% upside from current levels.
Is XERS stock overvalued or undervalued?
At a forward P/E of 50.9993x, XERS trades at a premium valuation. The consensus price target of $8.82 (19.2% upside) suggests analysts still see growth justifying the multiple.
How high can XERS stock go?
The most bullish Wall Street analyst has a price target of $18 for XERS, while the most conservative target is $4. The consensus of $8.82 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover XERS stock?
XERS is moderately covered, with 10 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the XERS stock forecast?
The 12-month XERS stock forecast based on 10 Wall Street analysts shows a consensus price target of $8.82, with estimates ranging from $4 (bear case) to $18 (bull case). The median consensus rating is "Buy".
What is XERS's forward P/E ratio?
XERS trades at a forward P/E ratio of 51.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 2312.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy XERS stock?
Wall Street analysts are optimistic on XERS, with a "Buy" consensus rating and $8.82 price target (19.2% upside). 9 of 10 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do XERS price targets vary so much?
XERS analyst price targets range from $4 to $18, a 159% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $8.82 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare